Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD
First Affiliated Hospital Xi'an Jiaotong University
Study Chair - Akter Kamal, MD, PhD
M Abdur Rahim Medical College Hospital
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chattogram General Hospital
Chittagong, Bangladesh
- Cox'S Bazar 250 Bed District Sadar Hospital
Cox’s Bāzār, Bangladesh
- M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh
- M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Aug 2020
- Primary completion
- 30 Jan 2021
- Completion
- 10 Feb 2021
- Last update posted
- 2 Apr 2021
- Registered enrollment
- 205
- Registry id
- NCT04678739
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.